Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.

About Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.

Biocytogen is a global biotechnology company focused on advancing innovative drug discovery and development. They provide comprehensive solutions from target identification to IND submission, leveraging proprietary gene-editing technologies and fully human antibody discovery platforms to accelerate preclinical research and therapeutic development.

Products & Services

Preclinical Animal Models and Services:Offers thousands of off-the-shelf drug-targeted humanized models through BioMice™, along with gene-editing and preclinical pharmacology services for drug efficacy, safety, and mechanistic studies in areas like oncology and immunology.

Fully Human Antibody Discovery Platforms:Utilizes SUPCE™ technology and the RenMice family (RenMab, RenLite, RenNano, RenTCR mimic) for monoclonal, bispecific, and TCR mimic antibody discovery, targeting diverse therapeutic areas.

Animal Models & Cell Lines:Includes gene humanized mouse models, immunodeficient models, knockout models, and cell lines for research purposes.

Gene Editing Services:Provides conventional and conditional knockout/knockin, point mutation, and transgenic mouse model services.

Efficacy & Toxicity Studies:Offers in vivo and in vitro pharmacology, PK/PD studies, and non-GLP toxicity studies for drug evaluation.

Therapeutic Area Solutions:Models and services tailored for oncology, autoimmune diseases, metabolism, neuroscience, ophthalmology, and cardiovascular diseases.

Drug Type Solutions:Supports development of bispecific antibodies, antibody-drug conjugates, cell therapy, gene therapy, oligonucleotides, vaccines, and small molecules.

Specialties

Gene Editing Technologies Fully Human Antibody Discovery Preclinical Pharmacology Animal and Cell Model Generation Oncology Research Immunology Therapeutic Antibody Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: IPO T: - FT: IPO	A: 3626000000 MR: - FA: 25.9 billion RMB FAN: 3626000000	D: 2025-12-09 FD: 2025-12-09	-

IPO Latest

2025-12-09

$3.6B

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Edward Rocheta

Vice President, Business Operations

Z

Zhongcong Xie

Director, Geriatric Anesthesia Research Unit; Director, Basic Science Research Department of Anesthesia, Critical Care and Pain Medicine, MGH

J

Joy Wang

Principal Scientist, Genomic Medicine Preclinical Pharmacology

Recent News